Breast Cancer News
In this section, access cutting-edge triple-negative breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Researchers suggest more studies be done on carboplatin to find out if it could have long-term benefits and to see what types of people with triple-negative breast cancer it helps most.
Researchers with the phase II GeparSixto trial found that women with triple-negative breast cancer were significantly more likely to achieve pathological complete response, or pCR, when carboplatin was added to their course of other anti-cancer medicines. For this study, pCR was defined as the absence of cancer after treatment given before surgery.
LBBC highlights two studies reported on the last day of the annual meeting of the American Society of Clinical Oncology: GeparSixto, which looked at the impact of adding a platinum chemotherapy to standard medicines given before surgery to people with triple-negative breast cancer and a family history of breast or ovarian cancer; and an analysis of the PAM50 genomic assay as a tool to help people with early-stage breast cancer make decisions about mastectomy versus lumpectomy and radiation.
The American Society of Clinical Oncology published updates to their 2005 guidelines for use of sentinel lymph node biopsy in early-stage breast cancer. The guidelines, based on the review of 9 randomized clinical trials and 13 cohort studies, reflect what ASCO believes are best practices in using the biopsy.
A recent study suggests that while women are living longer after treatment for breast cancer, they may be at greater risk of developing certain health conditions as they age.
According to a study recently published in the Journal of Clinical Oncology, practicing Hatha yoga for as few as 3 months may lessen fatigue and inflammation in people treated for breast cancer.
Each December, medical experts and researchers from around the world meet at the 5-day San Antonio Breast Cancer Symposium to share the latest findings from breast cancer clinical trials. Read on for updates from the 2013 symposium, held December 10–14.
(Reuters) - Women with an especially deadly type of breast cancer who received a treatment regimen containing an experimental AbbVie Inc drug prior to surgery are likely to have a significantly better response than those who get a standard chemotherapy regimen, according to data from a clinical trial.
A study suggests age-specific incidences of breast cancer subtypes vary by race, showing that the differences by race occur only when tumor subtypes are grouped together.
Research shows younger women given pre-surgical, or neoadjuvant, chemotherapy are more likely to have a complete response to that treatment than older women.